scholarly journals Knowledge Level of Physicians in Turkey about Hepatitis C and New Treatments

2021 ◽  
Vol 27 (3) ◽  
pp. 136-141
Author(s):  
Ayşegül İnci Sezen ◽  
Kadriye Kart Yaşar
Keyword(s):  
Hepatitis C ◽  
Knowledge Level ◽  
New Treatments

scholarly journals Hepatitis C: how has France limited the expenses related to new treatments?

2016 ◽  
Vol 16 (6) ◽  
pp. 655-657 ◽  
Author(s):  
Anne-Laure Mouterde ◽  
François Bocquet ◽  
Isabelle Fusier ◽  
Pascal Paubel
Keyword(s):  
Hepatitis C ◽  
New Treatments

scholarly journals Monoclonal Antibody AP33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E2 Envelope Glycoprotein

2005 ◽  
Vol 79 (17) ◽  
pp. 11095-11104 ◽  
Author(s):  
Ania Owsianka ◽  
Alexander W. Tarr ◽  
Vicky S. Juttla ◽  
Dimitri Lavillette ◽  
Birke Bartosch ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Envelope Glycoprotein ◽  
Envelope Protein ◽  
Hypervariable Region ◽  
Neutralizing Antibody ◽  
Broadly Neutralizing Antibody ◽  
New Treatments ◽  
Potent Neutralization

ABSTRACT Hepatitis C virus (HCV) remains a significant threat to the general health of the world's population, and there is a pressing need for the development of new treatments and preventative vaccines. Here, we describe the generation of retrovirus-based pseudoparticles (HCVpp) incorporating a panel of full-length E1E2 clones representative of the major genotypes 1 through 6, and their application to assess the reactivity and neutralizing capability of antisera and monoclonal antibodies raised against portions of the HCV E2 envelope protein. Rabbit antisera raised against either the first hypervariable region or ectodomain of E2 showed limited and strain specific neutralization. By contrast, the monoclonal antibody (MAb) AP33 demonstrated potent neutralization of infectivity against HCVpp carrying E1E2 representative of all genotypes tested. The concentration of AP33 required to achieve 50% inhibition of infection by HCVpp of diverse genotypes ranged from 0.6 to 32 μg/ml. The epitope recognized by MAb AP33 is linear and highly conserved across different genotypes of HCV. Thus, identification of a broadly neutralizing antibody that recognizes a linear epitope is likely to be of significant benefit to future vaccine and therapeutic antibody development.

Care and treatment of hepatitis C among Aboriginal people in New South Wales, Australia: implications for the implementation of new treatments

2015 ◽  
Vol 21 (1) ◽  
pp. 39-57 ◽  
Author(s):  
Carla Treloar ◽  
Clair Jackson ◽  
Rebecca Gray ◽  
Jamee Newland ◽  
Hannah Wilson ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Aboriginal People ◽  
New South ◽  
New South Wales ◽  
South Wales ◽  
Care And Treatment ◽  
New Treatments

Su1410 New Treatments for Chronic Hepatitis C: Outcomes and Compliance in an Urban Minority Population

2015 ◽  
Vol 148 (4) ◽  
pp. S-501
Author(s):  
Mel A. Ona ◽  
Kinesh Changela ◽  
Charilaos Papafragkakis ◽  
Tagore Sunkara ◽  
Andrea N. Culliford ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Minority Population ◽  
Urban Minority ◽  
New Treatments

Costs of New Treatments for Hepatitis C Infection

JAMA ◽  
2014 ◽  
Vol 312 (20) ◽  
pp. 2168 ◽  
Author(s):  
Ruth Lopert ◽  
Craig Welch
Keyword(s):  
Hepatitis C ◽  
Hepatitis C Infection ◽  
New Treatments

scholarly journals New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England

2016 ◽  
Vol 23 (8) ◽  
pp. 631-643 ◽  
Author(s):  
R. J. Harris ◽  
N. K. Martin ◽  
E. Rand ◽  
S. Mandal ◽  
D. Mutimer ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Hcv Transmission ◽  
New Treatments

scholarly journals Hepatitis C Variability, Patterns of Resistance, and Impact on Therapy

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Cristina Simona Strahotin ◽  
Michael Babich
Keyword(s):  
Hepatitis C ◽  
Antiviral Agents ◽  
Cost Effective ◽  
Standard Of Care ◽  
The United States ◽  
Resistance Mechanisms ◽  
Cost Effective Method ◽  
New Treatments ◽  
Cure Rates ◽  
Effective Treatments

Hepatitis C (HCV), a leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma, is the most common indication for liver transplantation in the United States. Although annual incidence of infection has declined since the 1980s, aging of the currently infected population is expected to result in an increase in HCV burden. HCV is prone to develop resistance to antiviral drugs, and despite considerable efforts to understand the virus for effective treatments, our knowledge remains incomplete. This paper reviews HCV resistance mechanisms, the traditional treatment with and the new standard of care for hepatitis C treatment. Although these new treatments remain PEG-IFN-α- and ribavirin-based, they add one of the newly FDA approved direct antiviral agents, telaprevir or boceprevir. This new “triple therapy” has resulted in greater viral cure rates, although treatment failure remains a possibility. The future may belong to nucleoside/nucleotide analogues, non-nucleoside RNA-dependent RNA polymerase inhibitors, or cyclophilin inhibitors, and the treatment of HCV may ultimately parallel that of HIV. However, research should focus not only on effective treatments, but also on the development of a HCV vaccine, as this may prove to be the most cost-effective method of eradicating this disease.

Sign in / Sign up

Export Citation Format

Share Document